Department of Internal Medicine, Asan Medical Center, Seoul, South Korea.
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Ann Hematol. 2020 Dec;99(12):2831-2836. doi: 10.1007/s00277-020-04284-z. Epub 2020 Sep 28.
The standard of treatment for completely resected limited-stage diffuse large B cell lymphoma (DLBCL) in patients without residual lesions has not yet been established. Previously, we designed a phase II trial to evaluate the safety and efficacy of three cycles of abbreviated R-CHOP in patients with completely resected limited-stage DLBCL and reported favorable survival outcomes. We present the long-term follow-up results to taking into account the importance of delayed relapse in patients with limited-stage DLBCL. With a median follow-up duration of 62.7 months (range, 60.2-75.5 months), the 5-year OS and DFS rates were both 95.0% (95% confidence interval, 85.59-104.11%). Only one patient experienced disease progression which was confirmed at 12.3 months, and one patient with primary intestinal DLBCL developed non-small cell lung cancer 6 years after treatment. The long-term results of our data support the use of three cycles of abbreviated R-CHOP for patients with completely resected limited-stage DLBCL. The study was reviewed and approved by the review boards of the participating institutes and registered at ClinicalTrials.gov , number NCT01279902, in August 3, 2010.
完全切除的局限性弥漫性大 B 细胞淋巴瘤（DLBCL）患者的标准治疗方法尚未确定。此前，我们设计了一项 II 期临床试验，以评估完全切除的局限性 DLBCL 患者接受三周期短疗程 R-CHOP 的安全性和有效性，并报告了良好的生存结果。我们考虑到局限性 DLBCL 患者延迟复发的重要性，现将长期随访结果呈现出来。中位随访时间为 62.7 个月（范围为 60.2-75.5 个月），5 年 OS 和 DFS 率均为 95.0%（95%置信区间，85.59-104.11%）。仅 1 例患者出现疾病进展，于 12.3 个月时确诊，1 例原发性肠道 DLBCL 患者在治疗 6 年后发生非小细胞肺癌。我们数据的长期结果支持对完全切除的局限性 DLBCL 患者使用三周期短疗程 R-CHOP。该研究经过参与机构的审查委员会审查和批准，并于 2010 年 8 月 3 日在 ClinicalTrials.gov 注册，编号为 NCT01279902。
